A triple-blind, placebo-controlled, randomized clinical trial of CANnabinoids for Drug Resistant Epilepsy (CAN-DRE) in adults and children

More than 260,000 people in Canada have epilepsy, and about 30% of people with epilepsy do not respond well to conventional therapies. Drug-resistant epilepsy (DRE) is when people do not respond to several seizure medications and is challenging for clinicians, patients, and caregivers.

This clinical trial is being done to compare changes in seizure frequency reported at maintenance phase compared to baseline.

We will enroll 90 participants who will be randomized 1:1:1 into one of three arms: arm 1 (control arm), arm 2 (CBD isolate arm), or arm 3 (CBD-enriched cannabis herbal extract arm)

June 2025 update

This study is currently under review with the Research Ethics Board.

This study was funded by the Canadian Institute for Health Research (CIHR) and Research Manitoba.

This study is registered with ClinicalTrials.gov, NCT07023744.